Related Experiment Video
Updated: Feb 14, 2026

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
Published on: October 5, 2020
EGFR-TKIs resistance via EGFR-independent signaling pathways
Qian Liu1, Shengnan Yu1, Weiheng Zhao1
1Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Abstract:
Tyrosine kinase inhibitors (TKIs)-treatments bring significant benefit for patients harboring epidermal growth factor receptor (EGFR) mutations, especially for those with lung cancer. Unfortunately, the majority of these patients ultimately develop to the acquired resistance after a period of treatment. Two central mechanisms are involved in the resistant process: EGFR secondary mutations and bypass signaling activations. In an EGFR-dependent manner, acquired mutations, such as T790 M, interferes the interaction between TKIs and the kinase domain of EGFR. While in an EGFR-independent manner, dysregulation of other receptor tyrosine kinases (RTKs) or abnormal activation of downstream compounds both have compensatory functions against the inhibition of EGFR through triggering phosphatidylinositol 3-kinase (PI3K)/Akt and mitogen-activated protein kinase (MAPK) signaling axes. Nowadays, many clinical trials aiming to overcome and prevent TKIs resistance in various cancers are ongoing or completed. EGFR-TKIs in accompany with the targeted agents for resistance-related factors afford a promising first-line strategy to further clinical application.
Insights
Tyrosine kinase inhibitors (TKIs) benefit EGFR-mutated lung cancer patients but acquired resistance develops. Understanding resistance mechanisms like EGFR mutations and bypass signaling is key to developing new combination therapies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Tyrosine kinase inhibitors (TKIs) are effective for EGFR-mutated cancers, particularly lung cancer.
- Acquired resistance limits the long-term efficacy of TKI treatments in most patients.
- Resistance mechanisms include secondary EGFR mutations and activation of bypass signaling pathways.
Purpose of the Study:
- To review the mechanisms of acquired resistance to EGFR-TKIs.
- To discuss strategies for overcoming TKI resistance in cancer treatment.
- To highlight the potential of combination therapies for improved clinical outcomes.
Main Methods:
- Literature review of studies on TKI resistance in EGFR-mutated cancers.
- Analysis of molecular mechanisms underlying acquired resistance.
- Evaluation of ongoing and completed clinical trials for resistance-targeting agents.
Main Results:
- Acquired resistance involves EGFR-dependent mechanisms (e.g., T790M mutation) and EGFR-independent mechanisms (e.g., RTK dysregulation, PI3K/Akt and MAPK pathway activation).
- These mechanisms confer compensatory signaling, overriding EGFR inhibition.
- Numerous clinical trials are investigating strategies to prevent or overcome TKI resistance.
Conclusions:
- Combination therapies involving EGFR-TKIs and agents targeting resistance mechanisms offer a promising strategy.
- This approach holds potential as a first-line treatment to improve patient outcomes in EGFR-mutated cancers.
- Further research and clinical trials are essential to optimize these combination strategies.
More Related Videos
Related Concept Videos
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
Hedgehog Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Non-Canonical Wnt Signaling Pathways
Canonical Wnt Signaling Pathway
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...

